Santhera Publishes Agenda for its Annual General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement...
Source: globenewswire.com
📰 Eva Kalias News
Page 2 - Eva Kalias News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eva Kalias. Real-time updates on events, politics, business and more.
Santhera Pharmaceuticals Holding AG: Santhera Publishes Agenda for its Annual General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland
Source: finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results
Switzerland General Eva Kalias Santhera Pharmaceuticals Holding Head Investor Relations Communications Santhera Pharmaceuticals Annual Report
Source: finanznachrichten.de
Stock Market | FinancialContent Business Page
FinancialContent fully hosted finance channel
United Kingdom United States Switzerland General Eva Kalias Santhera Pharmaceuticals Holding European Medicines Agency
Source: financialcontent.com
Santhera Publishes Annual Report 2022
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals announces the publication of its Annual Report 2022 with fully audited results... | May 31, 2023
Switzerland General United States United Kingdom Eva Kalias Chiesi Group Head Investor Relations Communications
Source: marketscreener.com
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 27, 2023, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news releas...
Source: pharmiweb.com
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 27, 2023, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from... | April 27, 2023
Source: marketscreener.com
Santhera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed
Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting
Source: finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, March 2, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory
Source: finanznachrichten.de
Santhera Pharmaceuticals Holding AG: Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, February 8, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a final reimbursement agreement with the
Source: finanznachrichten.de